In a cohort of 269,304 IBD patients, NSAID use showed a small increase in IBD-related hospitalisation (HR 1.08), meeting non-inferiority threshold (HR <1.2). No risk in UC (HR 0.96); modest risk in Crohn’s (HR 1.16). Relooks at the current paradigm of blanket NSAID avoidance in https://t.co/O8MWg1BP50

• https://x.com/synovialjoints/status/1982862356670480474/photo/1

56 pts w/tracheobronchial stenosis in GPA, highly frustrating disease manifestation Not surprising to see severe dx & prior intralesional tx assoc with incidence (ie necessity) of tracheal dilation Leflunomide protective? Have others seen this? #ACR @RheumNow Abstr#1596 https://t.co/djJXnAkxnv

• https://x.com/EBRheum/status/1982860846771437709/photo/1

Sun et al. Telitacicept in SARD-ILD (pSS, ASS, RA). 25 patients. Improvements in CT, PFTs, 6MWT. @RheumNow #ACR25 Abstr#1361 https://t.co/q679LOaOyL

• https://x.com/RichardPAConway/status/1982857071872622948/photo/1

In pooled analysis of 9 PsA trials, 6.9% of secukinumab-treated patients had fungal infections, mostly mild/moderate. Candida rates were low (1.86–2.18/100 PY) and didn’t increase over time. 89.7% resolved fully; only 0.8% led to discontinuation. Abstract 1459 @RheumNow #ACR25 https://t.co/kltMZVEDf9

• https://x.com/synovialjoints/status/1982854810463260751/photo/1

England et al. Predictors of progression RA-ILD - UIP pattern (HR 1.46), current (HR 1.98) and former (HR 1.60) smoking, age (HR 1.03). @RheumNow #ACR25 Abstr#1308 https://t.co/IvQo8Istta

• https://x.com/RichardPAConway/status/1982854555105947705/photo/1

Interim analysis of Ph3 TULIP-SC trial: Anifrolumab 120mg SC or PBO weekly + SOC x 52wks Primary endpt met: BICLA response w/Anifrolumab (60.3%) vs. PBO(43.9%)[p=0.014] Pts on Ani had sustained BICLA response upto wk 52 (HR 2.1) Promising results. #ACR25 @RheumNow Abs1545 https://t.co/nqse1BiGq2

• https://x.com/RHEUMarampa/status/1982853044934225957/photo/1
• https://x.com/RHEUMarampa/status/1982853044934225957/photo/1

In Sjögren’s, cancer risk is real. >9yr multicenter cohort (n=314), overall cancer risk ↑ (SIR 1.68), NHL >15× expected Predictors: older age, smoking, LAD, splenomegaly, cryoglobulinemia (strongest for lymphoma). Malignancies = 24% of deaths @RheumNow #ACR25 Abstract #1681

Pope @Janetbirdope et al. Parenteral (IM and/or IA) superior to oral steroids in early RA. Better discontinuation of steroids with no difference in need for advanced therapies. @RheumNow #ACR25 Abstr#1355 #ACRbest https://t.co/OyvnzEGlLE

• https://x.com/RichardPAConway/status/1982845746950164581/photo/1

In a prespecified exploratory analysis of REGENCY trial data by DrRovin et al, Bet. wks 24 and 76: Obinutuzumab ⬇️ LN flares vs. PBO (HR 0.44; p=0.0074) Pts on Obi had less unfavorable kidney outcomes vs. PBO (HR 0.37; p=0.0039) Addtl tx option for LN #ACR25 @RheumNow Abs1521 https://t.co/N5K9Nzh71E

• https://x.com/RHEUMarampa/status/1982844740291952655/photo/1

Post-hoc analysis of CARE(Ph2B) Study to assess sustained responses in mSLEDAI-2K vs. PBO x 12mos in pts given Cenerimod Sustained response in Cenerimod Ex-4mg (63.5%) > PBO (50%); HR 1.43 Ongoing research, further data needed. #ACR25 @RheumNow Abs1519 https://t.co/cQbVVIIyxW

• https://x.com/RHEUMarampa/status/1982843734011105721/photo/1

Infection data from SELECT-GCA: Glucocorticoids seem to drive overall infectious risk UPA use associated with higher zoster - vaccinate!! @RheumNow #ACR25 Abst# 0895 https://t.co/ueVbFPxG0Q

• https://x.com/Dr_Brian_MD/status/1982843521112641587/photo/1

Prednisone remains both lifeline and liability. New PRED-SAFE SDM tool helps patients and clinicians navigate that tension—visualizing benefits and harms to guide tapering. In pilot testing, 93% had no residual decisional conflict. @RheumNow #ACR25 Abstract#1052 #ACRbest https://t.co/CgQ75N7A1p

• https://x.com/JihaRheum/status/1982842223743164901/photo/1

Post Hoc analysis from SELECT-GCA Increased rate of herpes zoster for 26wk steroid-UPA 15mg (7.3% vs 4.2% 52wk steroid-plbo) but lower rate of SERIOUS infections (7.9% vs 12.7% 52wk steroid-plbo) Zoster risk is real; steroids are the bigger problem @Rheumnow #ACR25 Abstr#0895 https://t.co/IKzO2J4hLH

• https://x.com/EBRheum/status/1982839959070687309/photo/1
• https://x.com/EBRheum/status/1982839959070687309/photo/1
• https://x.com/EBRheum/status/1982839959070687309/photo/1

Rural RA care looks different but not less intensive: DMARD and GC use matched urban rates, yet rural pts often managed by PCPs had twice the opioid use. ACR's Rheum for Primary Care resource can help address access gap and improve RA care @RheumNow #ACR25 Abstract#1025

Liraglutide had decreased synovial inflammation and fibrosis in mouse models, however dexamethasone didnt have changes in fibrosis scores Abst#1734 #ACR25 @RheumNow https://t.co/O4JYGtDD5N

• https://x.com/bella_mehta/status/1982837788166017285/photo/1